Metabotropic glutamate receptors as targets for novel antipsychotic treatments

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1522-1534

  Gray, L J ^a,b   Hannan, A J ^c   Zhang, X ^b,d  

^a DEAKIN UNIVERSITY   (Australia)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antipsychotic; Metabotropic glutamate receptors; mGluR2; mGluR3; mGluR5; Schizophrenia

Indexed keywords

4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; ADENOSINE RECEPTOR; AMPA RECEPTOR; CALCINEURIN; CANNABINOID RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE RECEPTOR; DRUG RECEPTOR; EGLUMETAD; ENDOCANNABINOID ERECEPTOR; LY 314582; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; PHOSPHOLIPASE C BETA1; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN HOMER; PROTEIN KINASE C; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PHARMACEUTICAL CARE; PROTEIN INTERACTION; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 84862628456     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784817     Document Type: Article

References (185)

1. Roth, B.L.; Sheffler, D.J.; Kroeze, W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews Drug Discov., 2004, 3(4), 353-359.
2. Krystal, J.H.; Karper, L.P.; Seibyl, J.P.; Freeman, G.K.; Delaney, R.; Bremner, J.D.; Heninger, G.R.; Bowers, M.B. Jr.; Charney, D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry, 1994, 51(3), 199-214.
3. Krystal, J.H.; Bennett, A.; Abi-Saab, D.; Belger, A.; Karper, L.P.; D'Souza, D.C.; Lipschitz, D.; Abi-Dargham, A.; Charney, D.S. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol. Psychiatry, 2000, 47(2), 137-143.
4. Adler, C.M.; Malhotra, A.K.; Elman, I.; Goldberg, T.; Egan, M.; Pickar, D.; Breier, A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry, 1999, 156(10), 1646-1649.
5. Lahti, A.C.; Koffel, B.; LaPorte, D.; Tamminga, C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology, 1995, 13(1), 9-19.
6. Wang, C.; Kaufmann, J.A.; Sanchez-Ross, M.G.; Johnson, K.M. Mechanisms of N-methyl-D-aspartate-induced apoptosis in phencyclidine-treated cultured forebrain neurons. J. Pharmacol. Exp. Ther., 2000, 294(1), 287-295.
7. Choi, D.W.; Koh, J.Y.; Peters, S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J. Neurosci., 1988, 8(1), 185-196.
8. Kew, J.N.; Kemp, J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl), 2005, 179(1), 4-29.
9. Heilker, R.; Wolff, M.; Tautermann, C.S.; Bieler, M. G-proteincoupled receptor-focused drug discovery using a target class platform approach. Drug Discov. Today, 2009, 14(5-6), 231-240.
10. Conn, P.J.; Christopoulos, A.; Lindsley, C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov., 2009, 8(1), 41-54.
11. Conn, P.J.; Pin, J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol., 1997, 37, 205-237.
12. Abe, T.; Sugihara, H.; Nawa, H.; Shigemoto, R.; Mizuno, N.; Nakanishi, S. Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J. Biol. Chem., 1992, 267(19), 13361-13368.
13. Niswender, C.M.; Conn, P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol., 2010, 50, 295-322.
14. Brody, S.A.; Conquet, F.; Geyer, M.A. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology (Berl.), 2004, 172(2), 187-195.
15. Brody, S.A.; Dulawa, S.C.; Conquet, F.; Geyer, M.A. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol. Psychiatry, 2004, 9(1), 35-41.
16. Gray, L.; van den Buuse, M.; Scarr, E.; Dean, B.; Hannan, A.J. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int. J. Neuropsychopharmacol., 2009, 12(1), 45-60.
17. Henry, S.A.; Lehmann-Masten, V.; Gasparini, F.; Geyer, M.A.; Markou, A. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology, 2002, 43(8), 1199-1209.
18. Kinney, G.G.; Burno, M.; Campbell, U.C.; Hernandez, L.M.; Rodriguez, D.; Bristow, L.J.; Conn, P.J. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther., 2003, 306(1), 116-123.
19. Pietraszek, M.; Gravius, A.; Schäfer, D.; Weil, T.; Trifanova, D.; Danysz, W. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology, 2005, 49(1), 73-85.
20. Pietraszek, M.; Rogóz, Z.; Wolfarth, S.; Ossowska, K. Opposite influence of MPEP, an mGluR5 antagonist, on the locomotor hyperactivity induced by PCP and amphetamine. J. Physiol. Pharmacol., 2004, 55(3), 587-593.
21. Balschun, D.; Wetzel, W. Inhibition of mGluR5 blocks hippocampal LTP in vivo and spatial learning in rats. Pharmacol. Biochem. Behav., 2002, 73(2), 375-380.
22. Lu, Y.M.; Jia, Z.; Janus, C.; Henderson, J.T.; Gerlai, R.; Wojtowicz, J.M.; Roder, J.C. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentation (LTP) but normal CA3 LTP. J. Neurosci., 1997, 17(13), 5196-5205.
23. Schulz, B.; Fendt, M.; Gasparini F.; Lingenhöhl, K.; Kuhn, R.; Koch, M. The metabotropic glutamate receptor antagonist 2- methyl-6-(phenylethynyl)-pyradine (MPEP) blocks fear conditioning in rats. Neuropharmacology, 2001, 41(1), 1-7.
24. Fendt, M.; Schmid, S. Metabotropic glutamate receptors are involved in amygdaloid plasticity. Eur. J. Neurosci., 2002, 15(9), 1535-1541.
25. Rodrigues, S.M.; Bauer, E.P.; Farb, C.R.; Schafe, G.E.; LeDoux, J.E. The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentation in the lateral amygdala. J. Neurosci., 2002, 22(12), 5219-5229.
26. Schachtman, T.R.; Bills, C.; Ghinescu, R.; Murch, K.; Serfozo, P.; Simonyi, A. MPEP, a selective metabotropic glutamate receptor 5 antagonist, attenuates conditioned taste aversion in rats. Behav. Brain Res., 2003, 141(2), 177-182.
27. Naie, K.; Manahan-Vaughan, D. Regulation by metabotropic glutamate receptor 5 of LTP in the dentate gyrus of freely moving rats: relevance for learning and memory formation. Cereb. Cortex, 2004, 14(2), 189-198.
28. Manahan-Vaughan, D.; Braunewell, K.H. The metabotropic glutamate receptor, mGluR5, is a key determinant of good and bad spatial learning performance and hippocampal synaptic plasticity. Cereb. Cortex, 2005, 15(11), 1703-1713.
29. Gravius, A.; Pietraszek, M.; Schäfer, D.; Schmidt, W.J.; Danysz, W. Effects of mGlu1 and mGlu5 receptor antagonists on negatively reinforced learning. Behav. Pharmacol., 2005, 16(2), 113-121.
30. Barker, G.R.; Bashir, Z.I.; Brown, M.W.; Warburton, E.C. A temporally distinct role for group I and group II metabotropic glutamate receptors in object recognition memory. Learn. Mem., 2006, 13(2), 178-186.
31. Salinska, E. The role of group I metabotropic glutamate receptors in memory consolidation and reconsolidation in the passive avoidance task in 1-day-old chicks. Neurochem. Int., 2006, 48(6-7), 447-452.
32. Campbell, U.C.; Lalwani, K.; Hernandez, L.; Kinney, G.G.; Conn, P.J.; Bristow, L.J. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl.), 2004, 175(3), 310-318.
33. Tsai, G.E.; Lin, P.Y. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des., 2010; 16(5), 522-537.
34. Lane, H.Y.; Lin, C.H.; Huang, Y.J.; Liao, C.H.; Chang, Y.C.; Tsai, G.E. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol., 2010, 13(4), 451-460.
35. Coyle, J.T.; Tsai, G.; Goff, D.C. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Targets CNS Neurol. Disord., 2002, 1(2), 183-189.
36. Javitt, D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry, 2004, 9(11), 984-997.
37. Alagarsamy, S.; Rouse, S.T.; Junge, C.; Hubert, G.W.; Gutman, D.; Smith, Y.; Conn, P.J. NMDA-induced phosphorylation and regulation of mGluR5. Pharmacol. Biochem. Behav., 2002, 73(2), 299-306.
38. Awad, H.; Hubert, G.W.; Smith, Y.; Levey, A.I.; Conn, P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci., 2000, 20(21), 7871-7879.
39. Benquet, P.; Gee, C.E.; Gerber, U. Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. J. Neurosci., 2002, 22(22), 9679-9686.
40. Mannaioni, G.; Marino, M.J.; Valenti, O.; Traynelis, S.F.; Conn, P.J. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J. Neurosci., 2001, 21(16), 5925-5934.
41. Pisani, A.; Gubellini, P.; Bonsi, P.; Conquet, F.; Picconi, B.; Centonze, D.; Bernardi, G.; Calabresi, P. Metabotropic glutamate receptor 5 mediates the potentation of N-methyl-D-aspartate responses in medium spiny striatal meurons. Neuroscience, 2001, 106(3), 579-587.
42. Yang, L.; Mao, L.; Tang, Q.; Samdani, S.; Liu, Z.; Wang, J.Q. A novel Ca2+-independent signaling pathway to extracellular signalregulated protein kinase by coactivation of NMDA receptors and metabotropic glutamate receptor 5 in neurons. J. Neurosci., 2004, 24(48), 10846-10857.
43. Alagarsamy, S.; Saugstad, J.; Warren, L.; Mansuy, I.M.; Gereau, R.W. 4th.; Conn, P.J. NMDA-induced potentation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin. Neuropharmacology, 2005, 49(Suppl. 1), 135-145.
44. Harney, S.C.; Rowan, M.; Anwyl, R. Long-term depression of NMDA receptor-mediated synaptic transmission is dependent on activation of metabotropic glutamate receptors and is altered to long-term potentiation by low intracellular calcium buffering. J. Neurosci., 2006, 26(4), 1128-1132.
45. Choe, E.S.; Shin, E.H., Wang, J.Q. Regulation of phosphorylation of NMDA receptor NR1 subunits in the rat neostriatum by group I metabotropic glutamate receptors in vivo. Neurosci. Lett., 2006, 394(3), 246-251.
46. Gravius, A.; Pietraszek, M.; Schmidt, W.J.; Danysz, W. Functional interaction of NMDA and group I metabotropic glutamate receptors in negatively reinforced learning in rats. Psychopharmacology (Berl.), 2006, 185(1), 58-65.
47. Homayoun, H.; Stefani, M.R.; Adams, B.W.; Tamagan, G.D.; Moghaddam, B. Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. Neuropsychopharmacology, 2004, 29(7), 1259-1269.
48. Kishi, A.; Ohno, M.; Watanabe, S. Spermidine, a polyamine site agonist, attenuates working memory deficits caused by blockade of hippocampal muscarinic receptors and mGluRs in rats. Brain. Res., 1998, 793(1/2), 311-314.
49. Jia, Z.; Lu, Y.; Henderson, J.; Taverna, F.; Romano, C.; Abramow-Newerly, W.; Wojtowicz, J.M.; Roder, J. Selective abolition if the NMDA component of long-term potentiation in mice lacking mGluR5. Learn. Mem., 1998, 5(4/5), 331-343.
50. Coba, M.P.; Pocklington, A.J.; Collins, M.O.; Kopanitsa, M.V.; Uren, R.T.; Swamy, S.; Croning, M.D.; Choudhary, J.S.; Grant, S.G. Neurotransmitter drive combinatorial multistate postsynaptic density networks. Sci. Signal., 2009, 2(68), ra19.
51. Ahn, S.M.; Choe, E.S. Activation of group I metabotropic glutamate receptors increases serine phosphorylation of GluR1 alpha-amino-3-hydroxy-methylisoxazole-4-propionic acid receptors in the rat dorsal striatum. J. Pharmacol. Exp. Ther., 2009, 329(3), 1117-1126.
52. Ahn, S.M.; Choe, E.S. Alterations in GluR2 AMPA receptor phosphorylation at serine 880 following group I metabotropic glutamate receptor stimulation in the rat dorsal striatum. J. Neurosci. Res., 2010, 88(5), 992-999.
53. Uslaner, J.M.; Parmentier-Batteur, S.; Flick, R.B.; Surles, N.O.; Lam, J.S.; McNaughton, C.H.; Jacobson, M.A.; Hutson, P.H. Dosedependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology, 2009, 57(5-6), 531-538.
54. Lipina, T.; Weiss, K.; Roder, J. The ampakine CX546 restores the prepulse inhibition and latent inhibition deficits in mGluR5-deficient mice. Neuropsychopharmacology, 2007, 32(4), 745-756.
55. Bird, M.K.; Reid, C.A.; Chen, F.; Tan, H.O.; Petrou, S.; Lawrence, A.J. Cocaine-mediated synaptic potentiation is absent in VTA neurons from mGlu5-deficient mice. Int. J. Neuropsychopharmacol., 2010, 13(2), 133-141.
56. Tsou, K.; Brown, S.; Sañudo-Peña, M.C.; Mackie, K.; Walker, J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience, 1998, 83(2), 393-411.
57. Degenhardt, L.; Hall, W. Is cannabis use a contributory cause of psychosis? Can. J. Psychiatry, 2006, 51(9), 556-565.
58. Henquet, C.; Murray, R.; Linszen, D.; van Os, J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull., 2005, 31(3), 608-612.
59. Di Forti, M.; Morrison, P.D.; Butt, A.; Murray, R.M. Cannabis use and psychiatric and cogitive disorders: the chicken, or the egg? Curr. Opin. Psychiatry, 2007, 20(3), 228-234.
60. Fernandez-Espejo, E.; Viveros, M.P.; Núñez, L.; Ellenbroek, B.A.; Rodruigez de Fonseca, F. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl.), 2009, 206(4), 531-549.
61. D'Souza, D.C.; Perry, E.; MacDougall, L.; Ammerman, Y.; Cooper, T.; Wu, Y.T.; Braley, G.; Gueorguieva, R.; Krystal, J.H. The psychotomometic effects of intravenous delta-9-tetrahydrocannabinol in healthy individiuals: implications for psychosis. Neuropsychopharmacology, 2004, 29(8), 1558-1572.
62. Dean, B.; Sundream, S.; Bradbury, R.; Scarr, E.; Copolov, D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience, 2001, 103(1), 9-15.
63. Guidali, C.; Viganò, D.; Petrosino, S.; Zamberletti, E.; Realini, N.; Binelli, G.; Rubino, T.; Di Marzo, V.; Parolaro, D. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Int. J. Neuropsychopharmacol., 2011, 14(1), 17-28.
64. Ballmaier, M.; Bortolato, M.; Rizzetti, C.; Zoli, M.; Gessa, G.; Heinz, A.; Spano, P. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology, 2007, 32(10), 2098-2107.
65. Corbille, A.G.; Valjent, E.; Marsicano, G.; Ledent, C.; Lutz, B.; Hervé, D.; Girault, J.A. Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J. Neurosci., 2007, 27(26), 6937-6947.
66. Long, L.E.; Malone, D.T.; Taylor, D.A. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology, 2006, 31(4), 795-803.
67. Moreira, F.A.; Guimaraes, F.S. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur. J. Pharmacol., 2005, 512(2-3), 199-205.
68. Won, Y.J.; Puhl, H.L. 3rd.; Ikeda, S.R. Molecular reconstruction of mGluR5a-mediated endocannabinoid signaling cascade in single rat sympathetic neurons. J. Neurosci., 2009, 29(43), 13603-13612.
69. Lafourcade, M.; Elezgarai, I.; Mato, S.; Bakiri, Y.; Grandes, P.; Manzoni, O.J. Molecular components and functions of the endocannabinoid system in mouse cortex. PLoS ONE, 2007, 2, e709.
70. Robbe, D.; Kopf, M.; Remaury, A.; Bockaert, J.; Manzoni, O.J. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc. Natl. Acad. Sci. USA, 2002, 99(12), 8384-8388.
71. Ohno-Shosaku, T.; Maejima, T.; Kano, M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron, 2001, 29(3), 729-738.
72. Maejima, T.; Hashimoto, K.; Yoshida, T.; Aiba, A.; Kano, M. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron, 2001, 31(3), 463-475.
73. Grueter, B.A.; Gosnell, H.B.; Olsen, C.M.; Schramm-Sapyta, N.L.; Nekrasova, T.; Landreth, G.E.; Winder, D.G. Extracellular-signal regulated kinase 1-dependent metabotropic glutamate receptor 5-induced long-term depression in the bed nucleus of the stria terminalis is disrupted by cocaine administration. J. Neurosci., 2006, 26(12), 3210-3219.
74. Centonze, D.; Rossi, S.; Prosperetti, C.; Gasperi, V.; de Chiara, V.; Bari, M.; Tscherter, A.; Febbraro, F.; Bernardi, G.; Maccarrone, M. Endocannabinoids limit metabotropic glutamate 5 receptormediated synaptic inhibition of striatal principal neurons. Mol. Cell. Neurosci., 2007, 35(2), 302-310.
75. Varma, N.; Carlson, G.C.; Ledent, C.; Alger, B.E. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci., 2001, 21(24), RC188.
76. Edwards, D.A.; Zhang, L.; Alger, B.E. Metaplastic control of the endocannabinoid system at inhibitory synapses in hippocampus. Proc. Natl. Acad. Sci. USA, 2008, 105(23), 8142-8147.
77. Tzavara, E.T.; Degroot, A.; Wade, M.R.; Davis, R.J.; Nomikos, G.G. CB1 receptor knockout mice are hyporesponsive to the behaviour-stimulating actions of d-amphetamine: role of mGlu5 receptors. Eur Neuropsychopharmacol., 2009, 19(3), 196-204.
78. Sidiropoulou, K.; Lu, F.M.; Fowler, M.A.; Xiao, R.; Phillips, C.; Ozkan, E.D.; Zhu, M.X.; White, F.J.; Cooper, D.C. Dopamine modulates an mGluR5-mediated depolarization underlying prefrontal persistent activity. Nat. Neurosci., 2009, 12(2), 190-199.
79. Chiamulera, C.; Epping-Jordan, M.P.; Zocchi, A.; Marcon, C.; Cottiny, C.; Tacconi, S.; Corsi, M.; Orzi, F.; Conquet, F. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci., 2001, 4(9), 873-874.
80. Rouillon, C.; Degoulet, M.; Chevallier, K.; Abraini, J.H.; David, H.N. Modulation by group I mGLU receptor activation and group III mGLU receptor blockade of locomotor responses induced by D1-like and D2-like receptor agonists in the nucleus accumbens. Brain Res., 2008, 1198, 44-54.
81. David, H.N.; Abraini, J.H. The group I metabotropic glutamate receptor antagonist S-4-CPG modulates the locomotor response produced by the activation of D1-like, but not D2-like, dopamine receptors in the rat nucleus accumbens. Eur. J. Neurosci., 2001, 13(11), 2157-2164.
82. Diaz-Cabiale, Z.; Vivó M.; Del Arco, A.; O'connor, W.T.; Harte, M.K.; Müller, C.E.; Martínez, E.; Popoli, P.; Fuxe, K.; Ferré, S. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci. Lett., 2002, 324(2), 154-158.
83. Adams, C.L.; Cowen, M.S.; Short, J.L.; Lawrence A.J. Combined antagonism of glutamate mGlu5 and adenosine A2A receptors interact to regulate alcohol-seeking in rats. Int. J. Neuropsychopharmacol., 2008, 11(2), 229-241.
84. Kachroo, A.; Orlando, L.R.; Grandy, D.K.; Chen, J.F.; Young, A.B.; Schwarzschild, M.A. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J. Neurosci., 2005, 25(45), 10414-10419.
85. Ferré, S.; Karcz-Kubicha, M.; Hope, B.T.; Popoli, P.; Burgueño, J.; Gutiérrez, M.A.; Casadó, V.; Fuxe, K.; Goldberg, S.R.; Lluis, C.; Franco, R.; Ciruela, F. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. USA, 2002, 99(18), 11940-11945.
86. Rodrigues, R.J.; Alfaro, T.M.; Rebola, N.; Oliveira, C.R.; Cunha, R.A. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem., 2005, 92(3), 433-441.
87. Cabello, N.; Gandía, J.; Bertarelli, D.C.; Watanabe, M.; Lluís, C.; Franco, R.; Luján, R.; Ciruela, F. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J. Neurochem., 2009, 109(5), 1497-1507.
88. Popoli, P.; Pèzzola, A.; Torvinen, M.; Reggio, R.; Pintor, A.; Scarchilli, L.; Fuxe, K.; Ferré, S. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6- hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology, 2001, 25(4), 505-513.
89. Franco, R. Neurotransmitter receptor heteromers in neurodegenerative diseases and neural plasticity. J. Neural Transm., 2009, 116(8), 983-987.
90. Soloviev, M.M.; Ciruela, F.; Chan, W.Y.; Mcllhinney, R.A. Mouse brain and muscle tissues constitutively express high levels of Homer proteins. Eur. J. Biochem., 2000, 267(3), 634-639.
91. Tu, J.C.; Xiao, B.; Naisbitt, S.; Yuan, J.P.; Petralia, R.S.; Brakeman, P.; Doan, A.; Aakalu, V.K.; Lanahan, A.A.; Sheng, M.; Worley, P.F. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron, 1999, 23(3), 583-592.
92. Iasevoli, F.; Polese, D.; Ambesi-Impiombato, A.; Muscettola, G.; de Bartolomeis, A. Ketamine-related expression of glutamatergic postsynaptic density genes: possible implications in psychosis. Neurosci. Lett., 2007, 416(1), 1-5.
93. Thomas, U. Modulation of synaptic signalling complexes by Homer proteins. J. Neurochem., 2002, 81(3), 407-413.
94. Roloff, A.M.; Anderson, G.R.; Martemyanov, K.A.; Thayer, S.A. Homer 1a gates the induction mechanism for endocannabinoidmediated synaptic plasticity. J. Neurosci., 2010, 30(8), 3072-3081.
95. Szumlinski, K.K.; Lominac, K.D.; Kleschen, M.J.; Oleson, E.B.; Dehoff, M.H.; Schwarz, M.K.; Seeburg, P.H.; Worley, P.F.; Kalivas, P.W. Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. Genes Brain Behav., 2005, 4(5), 273-288.
96. Tomasetti, C.; Dell'Aversano, C.; Iasevoli, F.; de Bartolomeis, A. Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience, 2007, 150(1), 144-158.
97. Polese, D. de Serpis, A.A.; Ambesi-Impiombato, A.; Muscettola, G.; de Bartolomeis, A. Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine. Neuropsychopharmacology, 2002, 27(6), 906-913.
98. Choi, S.Y.; Chang, J.; Jiang, B.; Seol, G.H.; Min, S.S.; Han, J.S.; Shin, H.S.; Gallagher, M.; Kirkwood, A. Multiple receptors coupled to phospholipase C gate long-term depression in visual cortex. J. Neurosci., 2005, 25(49), 11433-11443.
99. Hashimotodani, Y.; Ohno-Shosaku, T.; Watanabe, M.; Kano, M. Roles of phospholipase Cbeta and NMDA receptor in activitydependent endocannabinoid release. J. Physiol., 2007, 584(pt. 2), 373-380.
100. Netzeband, J.G.; Conroy, S.M.; Parsons, K.L.; Gruol, D.L. Cannabinoids enhance NMDA-elicited Ca2+ signals in cerebellar granule neurons in culture. J. Neurosci., 1999, 19(20), 8765-8777.
101. Nevian, T.; Sakmann, B. Spine Ca2+ signaling in spike-timingdependent plasticity. J. Neurosci., 2006, 26(43), 11001-11013.
102. Horne, E.A.; Dell'Acqua, M.L. Phospholipase C is required for changes in postsynaptic structure and function associated with NMDA receptor-dependent long-term depression. J. Neurosci., 2007, 27(13), 3523-3534.
103. McOmish, C.E.; Burrows, E.; Howard, M.; Scarr, E.; Kim, D.; Shin, H.S.; Dean, B.; van den Buuse, M.; hannan, A.J. Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. Mol. Psychiatry, 2007, 13(7), 661-672.
104. Gray, L.; McOmish, C.E.; Scarr, E.; Dean, B.; Hannan, A.J. Sensitivity to MK-801 in phospholipase C-β1 knockout mice reveals a specific NMDA receptor deficit. Int. J. Neuropsychopharmacol., 2009, 12(7), 917-928.
105. Hannan, A.J.; Blakemore, C.; Katsnelson, A.; Vitalis, T.; Huber, K.M.; Bear, M.; Roder, J.; Kim, D.; Shin, H.S.; Kind, P.C. PLCbeta1, activated via mGluRs, mediates activity-dependent differentiation in cerebral cortex. Nat Neurosci., 2001, 4(3), 282-288.
106. Spires, T.L.; Molnár, Z.; Kind, P.C.; Cordery, P.M.; Upton, A.L.; Blakemore, C.; Hannan, A.J. Acitivity-dependent regulation of synapse and dendritic spine morphology in developing barrel cortex requires phospholipase C-beta1 signalling. Cereb. Cortex, 2005, 15(4), 385-393.
107. Morishita, W.; Connor, J.H.; Xia, H.; Quinlan, E.M.; Shenolikar, S.; Malenka, R.C. Regulation of synpatic strength by protein phosphatase 1. Neuron, 2001, 32(6), 1133-1148.
108. Lin, C.H.; Lee, C.C.; Gean, P.W. Involvement of a calcineurin cascade in amygdala depotentiation and quenching of fear memory. Mol. Pharmacol., 2003, 63(1), 44-52.
109. Kahan, B.D. Immunosuppressive therapy with cyclosporine for cardiac transplantation. Circulation, 1987, 75(1), 40-56.
110. Bahi, A.; Mineur, Y.S.; Picciotto, M.R. Blockade of protein phosphatase 2B activity in the amygdala increases anxiety- and depression-like behaviors in mice. Biol. Psychiatry, 2009, 66(12), 1139-1146.
111. Eastwood, S.L.; Burnet, P.W.; Harrison, P.J. Decreased hippocampal expression of the susceptibility gene PPP3CC and other calcineurin subunits in schizophrenia. Biol. Psychiatry, 2005, 57(7), 702-710.
112. Liu, Y.L.; Fann, C.S.; Liu, C.M.; Chang, C.C.; Yang, W.C.; Hung, S.I.; Yu, S.L.; Hwang, T.J.; Hsieh, M.H.; Liu, C.C.; Tsuang, M.M.; Wu, J.Y.; Jou, Y.S.; Faraone, S.V.; Tsuang, M.T.; Chen, W.J.; Hwu, H.G. More evidence supports the association of PPP3CC with schizophrenia. Mol. Psychiatry, 2007, 12(10), 966-974.
113. Miyakawa, T.; Leiter, L.M.; Gerber, D.J.; Gainetdinov, R.R.; Sotnikova, T.D.; Zeng, H.; Caron, M.G.; Tonegawa, S. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc. Natl. Acad. Sci. USA, 2003, 100(15), 8987-8992.
114. Rushlow, W.J.; Seah, Y.H.; Belliveau, D.J.; Rajakumar, N. Changes in calcineurin expression induced in the rat brain by the administration of antipsychotics. J. Neurochem., 2005, 94(3), 587-596.
115. Croci, C.; Sticht, H.; Brandstätter, J.H.; Enz, R. Group I metabotropic glutamate receptors bind to protein phosphatase 1C. Mapping and modeling of interacting sequences. J. Biol. Chem., 2003, 278(50), 50682-50690.
116. Sistiaga, A.; Sanchez-Prieto, J. Protein phosphatase 1 and 2A inhibitors prolong the switch in the control of glutamate release by group I metabotropic glutamate receptors: characterization of the inhibitory pathway. J. Neurochem., 2000, 75(4), 1566-1574.
117. Chen, H.H.; Stoker, A.; Markou, A. The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice. Psychopharmacology (Berl.), 2010, 209(4), 343-350.
118. Suzuki, T.; Okumura-Noji, K.; Tanaka, R.; Ogura, A.; Nakamura, K.; Kudo, Y.; Tada, T. Characterization of protein kinase C activities in postsynaptic density fractions prepared from cerebral cortex, hippocampus, and cerebellum. Brain. Res., 1993, 619(1-2), 69-75.
119. MacDonald, J.F.; Kotecha, S.A.; Lu, W.Y.; Jackson, M.F. Convergence of PKC-dependent kinase signal cascades on NMDA receptors. Curr. Drug Targets, 2001, 2(3), 299-312.
120. Chan, M.H.; Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice. Psychopharmacology (Berl.), 2008, 198(1), 141-148.
121. O'Brien, J.A.; Lemaire, W.; Chen, T.B.; Chang, R.S.; Jacobson, M.A.; Ha, S.N.; Lindsley, C.W.; Schaffhauser, H.J.; Sur, C.; Pettibone, D.J.; Conn, P.J.; Williams, D.L. Jr. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol. Pharmacol., 2003, 64(3), 731-740.
122. Kanuma, K.; Aoki, T.; Shimazaki, Y. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia. Recent Pat. CNS Drug Discov., 2010, 5(1), 23-34.
123. Kinney, G.G.; O'Brien, J.A.; Lemaire, W.; Burno, M.; Bickel, D.J.; Clements, M.K.; Chen, T.B.; Wisnoski, D.D.; Lindsley, C.W.; Tiller, P.R.; Smith, S.; Jacobson, M.A.; Sur, C.; Duggan, M.E.; Pettibone, D.J.; Conn, P.J.; Williams, D.L. Jr. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther., 2005, 313(1), 199-206.
124. Lindsley, C.W.; Wisnoski, D.D.; Leister, W.H.; O'brien, J.A.; Lemaire, W.; Williams, D.L. Jr.; Burno, M.; Sur, C.; Kinney, G.G.; Pettibone, D.J.; Tiller, P.R.; Smith, S.; Duggan, M.E.; Hartman, G.D.; Conn, P.J.; Huff, J.R. Discovery of positive allosteric modulators for the matbotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J. Med. Chem., 2004, 47(24), 5825-5828.
125. Vardigan, J.D.; Huszar, S.L.; McNaughton, C.H.; Hutson, P.H.; Uslaner, J.M. MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia? Pharmacol. Biochem. Behav., 2010, 95(2), 223-229.
126. Lecourtier, L.; Homayoun, H.; Tamagnan, G.; Moghaddam, B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonistinduced alteration of neuronal firing in prefrontal cortex. Biol. Psychiatry, 2007, 62(7), 739-746.
127. Liu, F.; Grauer, S.; Kelley, C.; Navarra, R.; Graf, R.; Zhang, G.; Atkinson, P.J.; Popiolek, M.; Wantuch, C.; Khawaja, X.; Smith, D.; Olsen, M.; Kouranova, E.; Lai, M.; Pruthi, F.; Pulicicchio, C.; Day, M.; Gilbert, A.; Pausch, M.H.; Brandon, N.J.; Beyer, C.E.; Comery, T.A.; Logue, S.; Rosenzweig-Lipson, S.; Marquis, K.L. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol. Exp. Ther., 2008, 327(3), 827-839.
128. Schlumberger, C.; Pietraszek, M.; Gravius, A.; Klein, K.U.; Greco, S.; Morè, L.; Danysz, W. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur. J. Pharmacol., 2009, 623(1-3), 73-83.
129. Schlumberger, C.; Pietraszek, M.; Gravius, A.; Danysz, W. Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia. Pharmacol. Biochem. Behav., 2010, 95(1), 23-30.
130. Ferraguti, F.; Shigemoto, R. Metabotropic glutamate receptors. Cell Tissue Res., 2006, 326(2), 483-504.
131. Petralia, R.S.; Wang, Y.X.; Niedzielski, A.S.; Wenthold, R.J. The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience, 1996, 71(4), 949-976.
132. Farazifard, R.; Wu, S.H. Metabotropic glutamate receptors modulate glutamatergic and GABAergic synpatic transmission in the central nucleus of the inferior colliculus. Brain Res., 2010, 1325, 28-40.
133. Moreno, J.L.; Sealfon, S.C.; Gonzalez-Maeso, J. Group II metabotropic glutamate receptors and schizophrenia. Cell Mol. Life Sci., 2009, 66(23), 3777-3785.
134. Sartorius, L.J.; Weinberger, D.R.; Hyde, T.M.; Harrison, P.J.; Kleinman, J.E.; Lipska, B.K. Expression of a GRM3 splice variant increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology, 2008, 33(11), 2626-2634.
135. Fujii, Y.; Shibata, H.; Kikuta, R.; Makino, C.; Tani, A.; Hirata, N.; Shibata, A.; Ninomiya, H.; Tashiro, N.; Fukumaki, Y. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr. Genet., 2003, 13(2), 71-76.
136. Egan, M.F.; Straub, R.E.; Goldberg, T.E.; Yakub, I.; Callicott, J.H.; Hariri, A.R.; Mattay, V.S.; Bertolino, A.; Hyde, T.M.; Shannon-Weickert, C.; Akil, M.; Crook, J.; Vakkalanka, R.K.; Balkissoon, R.; Gibbs, R.A.; Kleinman, J.E.; Weinberger, D.R. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. USA, 2004, 101(34), 12604-12609.
137. Norton, N.; Williams, H.J.; Dwyer, S.; Ivanov, D.; Preece, A.C.; Gerrish, A.; Williams, N.M.; Yerassimou, P.; Zammit, S.; O'Donovan, M.C.; Owen, M.J. No evidence for association between polymorphisms in GRM3 and schizophrenia. BMC Psychiatry, 2005, 5, 23.
138. Schwab, S.G.; Plummer, C.; Albus, M.; Borrmann-Hassenbach, M.; Lerer, B.; Trixler, M.; Maier, W.; Wildenauer, D.B. DANN sequence variants in the metabotropic glutamate receptor 3 and risk to schizophrenia: an association study. Psychiatr. Genet., 2008, 18(1), 25-30.
139. Nunokawa, A.; Watanabe, Y.; Kitamura, H.; Kaneko, N.; Arinami, T.; Ujike, H.; Inada, T.; Iwata, N.; Kunugi, H.; Itokawa, M.; Ozaki, N.; Someya, T. Large-scale case-control study of a functional polymorphism in the glutamate receptor, metabotropic 3 gene in patients with schizophrenia. Psychiatry Clin. Neurosci., 2008, 62(2), 239-240.
140. Moises, H.W.; Yang, L.; Kristbjarnarson, H.; Wiese, C.; Byerley, W.; Macciardi, F.; Arolt, V.; Blackwood, D.; Liu, X.; Sjögren, B.; Aschauer, H.N.; Hwu, H.-G.; Jang, K.; Livesley, W.J.; Kennedy, J.L.; Zoega, T.; Ivarsson, O.; Bui, M.-T.; Yu, M.-H.; Havsteen, B.; Commenges, D.; Weissenbach, J.; Schwinger, E.; Gottesmanm, I.I.; Pakstis, A.J.; Wetterberg, L.; Kidd, K.K.; Helgason, T. An international two-stage genome-wide search for schizophrenia susceptibility genes. Nat. Genet., 1995, 11(3), 321-324.
141. Blouin, J.L.; Dombroski, B.A.; Nath, S.K.; Lasseter, V.K.; Wolyniec, P.S.; Nestadt, G.; Thornquist, M.; Ullrich, G.; McGrath, J.; Kasch, L.; Lamacz, M.; Thomas, M.G.; Gehrig, C.; Radhakrishna, U.; Snyder, S.E.; Balk, K.G.; Neufeld, K.; Swartz, K.L.; DeMarchi, N.; Papadimitriou, G.N.; Dikeos, D.G.; Stefanis, C.N.; Chakravarti, A.; Childs, B.; Housman, D.E.; Kazazian, H.H.; Antonarakis, S.; Pulver, A.E. Schizophrenia, susceptibility loci on chromosomes 13q32 and 8p21. Nat. Genet., 1998, 20(1), 70-73.
142. Faraone, S.V.; Matise, T.; Svrakic, D.; Pepple, J.; Malaspina, D.; Suarez, B.; Hampe, C.; Zambuto, C.T.; Schmitt, K.; Meyer, J.; Markel, P.; Lee, H.; Harkavy Friedman, J.; Kaufmann, C.; Cloninger, C.R.; Tsuang, M.T. Genome scan of European-American schizophrenia pedigrees: results of the NIMH Genetics Initiative and Millennium Consortium. Am. J. Med. Genet., 1998, 81(4), 290-295.
143. Riley, B.P.; Makoff, A.; Mogudi-Carter, M.; Jenkins, T.; Williamson, R.; Collier, D.; Murray, R. Haplotype transmission disequilibrium and evidence for linkage if the CHRNA7 gene region to schizophrenia in Southern African Bantu families. Am. J. Med. Genet., 2000, 96(2), 196-201.
144. Joo, A.; Shibata, H.; Ninomiya, H.; Kawasaki, H.; Tashiro, N.; Fukumaki, Y. Structure and polymorphisms of the human metabotropic glutamate receptor type 2 gene (GRM2): analysis of association with schizophrenia. Mol. Psychiatry, 2001, 6(2), 186-192.
145. Ghose, S.; Gleason, K.A.; Potts, B.W.; Lewis-Amezcua, K.; Tamminga, C.A. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am. J. Psychiatry, 2009, 166(7), 812-820.
146. Crook, J.M.; Akil, M.; Law, B.C.; Hyde, T.M.; Kleinman, J.E. Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol. Psychiatry, 2002, 7(2), 157-164.
147. Ohnuma, T.; Augood, S.J.; Arai, H.; McKenna, P.J.; Emson, P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res. Mol. Brain Res., 1998, 56(1-2), 207-217.
148. Richardson-Burns, S.M.; Haroutunian, V.; Davis, K.L.; Watson, S.J.; Meador-Woodruff, J.H. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol.Psychiatry, 2000, 47(1), 22-28.
149. Ghose, S.; Crook, J.M.; Bartus, C.L.; Sherman, T.G.; Herman, M.M.; Hyde, T.M.; Kleinman, J.E.; Akil, M. Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia. Int. J. Neurosci., 2008, 118(11), 1609-1627.
150. Bullock, W.M.; Cardon, K.; Bustillo, J.; Roberts, R.C.; Perrone-Bizzozero, N.I. Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am. J. Psychiatry, 2008, 165(12), 1594-1603.
151. Morishima, Y.; Miyakawa, T.; Furuyashiki, T.; Mizuma, H.; Nakanishi, S. Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice. Proc. Natl. Acad. Sci. USA, 2005, 102(11), 4170-4175.
152. Linden, A.M.; Shannon, H.; Baez, M.; Yu, J.L.; Koester, A.; Schoepp, D.D. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice. Psychopharmacology (Berl.), 2005, 179(1), 284-291.
153. Woolley, M.L.; Pemberton, D.J.; Bate, S.; Corti, C.; Jones, D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl.), 2008, 196(3), 431-440.
154. Seeman, P.; Battaglia, G.; Corti, C.; Corsi, M.; Bruno, V. Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2(High) receptors and marked supersensitivity to the dopamine agonist (+)PHNO. Synapse, 2009, 63(3), 247-251.
155. Lyon, L.; Kew, J.N.; Corti, C.; Harrison, P.J.; Burnet, P.W. Altered hippocampal expression of glutamate receptors and transporters in GRM2 and GRM3 knockout mice. Synapse, 2008, 62(11), 842-850.
156. Olszewski, R.T.; Wegorzewska, M.M.; Monteiro, A.C.; Krolikowski, K.A.; Zhou, J.; Kozikowski, A.P.; Long, K.; Mastropaolo, J.; Deutsch, S.I.; Neale, J.H. Phencyclidine and dizocilpine induced behaviors reduced by Nacetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol. Psychiatry, 2008, 63(1), 86-91.
157. Bespalov, A.; Jongen-Rêlo, A.L.; van Gaalen, M.; Harich, S.; Schoemaker, H.; Gross, G. Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. J. Pharmacol. Exp. Ther., 2007, 320(2), 944-950.
158. Rorick-Kehn, L.M.; Johnson, B.G.; Knitowski, K.M.; Salhoff, C.R.; Witkin, J.M.; Perry, K.W.; Griffey, K.I.; Tizzano, J.P.; Monn, J.A.; McKinzie, D.L.; Schoepp, D.D. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal modes of psychiatric disorders. Psychopharmacology (Berl.), 2007, 193(1), 121-136.
159. Patil, S.T.; Zhang, L.; Martenyi, F.; Lowe, S.L.; Jackson, K.A.; Andreev, B.V.; Avedisova, A.S.; Bardenstein, L.M.; Gurovich, I.Y.; Morozova, M.A.; Mosolov, S.N.; Neznanov, N.G.; Reznik, A.M.; Smulevich, A.B.; Tochilov, V.A.; Johnson, B.G.; Monn, J.A.; Schoepp, D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med., 2007, 13(9), 1102-1107.
160. Imre, G.; Salomons, A.; Jongsma, M.; Fokkema, D.S.; den Boer, J.A.; Ter Horst, G.J. Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat. Pharmacol. Biochem. Behav., 2006, 84(3), 392-399.
161. Harich, S.; Gross, G.; Bespalov, A. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl.), 2007, 192(4), 511-519.
162. Krystal, J.H.; Abi-Saab, W.; Perry, E.; D'Souza, D.C.; Liu, N.; Gueorguieva, R.; McDougall, L.; Hunsberger, T.; Belger, A.; Levine, L.; Breier, A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl), 2005, 179(1), 303-309.
163. Fell, M.J.; Svensson, K.A.; Johnson, B.G.; Schoepp, D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther., 2008, 326(1), 209-217.
164. Spooren, W.P.; Gasparini, F.; van der Putten, H.; Koller, M.; Nakanishi, S.; Kuhn, R. Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur. J. Pharmacol., 2000, 397(1), R1-2.
165. Galici, R.; Echemendia, N.G.; Rodriguez, A.L.; Conn, P.J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther., 2005, 315(3), 1181-1187.
166. Benneyworth, M.A.; Xiang, Z.; Smith, R.L.; Garcia, E.E.; Conn, P.J.; Sanders-Bush, E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol. Pharmacol., 2007, 72(2), 477-484.
167. Galici, R.; Jones, C.K.; Hemstapat, K.; Nong, Y.; Echemendia, N.G.; Williams, L.C.; de Paulis, T.; Conn, P.J. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther., 2006, 318(1), 173-185.
168. Meltzer, H.Y.; Li, Z.; Kaneda, Y.; Ichikawa, J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27(7), 1159-1172.
169. Marek, G.J. Metabotropic glutamate 2/3 receptors as drug targets. Curr. Opin. Pharmacol., 2004, 4(1), 18-22.
170. Gonzalez-Maeso, J.; Ang, R.L.; Yuen, T.; Chan, P.; Weisstaub, N.V.; López-Giménez, J.F.; Zhou, M.; Okawa, Y.; Callado, L.F.; Milligan, G.; Gingrich, J.A.; Filizola, M.; Meana, J.J.; Sealfon, S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452(7183), 93-97.
171. Marek, G.J.; Wright, R.A.; Schoepp, D.D.; Monn, J.A.; Aghajanian, G.K. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther., 2000, 292(1), 76-87.
172. Uslaner, J.M.; Smith, S.M.; Huszar, S.L.; Pachmerhiwala, R.; Hinchliffe, R.M.; Vardigan, J.D.; Hutson, P.H. Combined administration of an mGlu2/3 receptor agoniost and a 5-HAT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants. Psychopharmacology (Berl.), 2009, 206(4), 641-651.
173. Gewirtz, J.C.; Marek, G.J. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology, 2000, 23(5), 569-576.
174. Homayoun, H.; Jackson, M.E.; Moghaddam, B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J. Neurophysiol., 2005, 93(4), 1989-2001.
175. Moghaddam, B.; Adams, B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science, 1998, 281(5381), 1349-1352.
176. Tyszkiewicz, J.P.; Gu, Z.; Wang, X.; Cai, X.; Yan, Z. Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C-dependent mechanism in pyramidal neurons of rat prefrontal cortex. J. Physiol., 2004, 554(pt. 3), 765-777.
177. Mela, F.; Marti, M.; Fiorentini, C.; Missale, C.; Morari, M. Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine. Mol. Cell. Neurosci., 2006, 31(2), 284-292.
178. Harris, S.L.; Cho, K.; Bashir, Z.I.; Molnar, E. Metabotropic glutamate receptor signalling in perirhinal cortical neurons. Mol. Cell. Neurosci., 2004, 25(2), 275-287.
179. Schaffhauser, H.; Cai, Z.; Hubalek, F.; Macek, T.A.; Pohl, J.; Murphy T.J.; Conn, P.J. cAMP-dependent protein kinase inhibits mGluR2 coupling to G-proteins by direct receptor phosphorylation. J. Neurosci., 2000, 20(15), 5663-5670.
180. Cai, Z.; Saugstad, J.A.; Sorensen, S.D.; Ciombor, K.J.; Zhang, C.; Schaffhauser, H.; Hubalek, F.; Pohl, J.; Duvoisin R.M.; Conn, P.J. Cyclic AMP-dependent protein kinase phosphorylates group III metabotropic glutamate receptors and inhibits their function as presynaptic receptors. J. Neurochem., 2001, 78(4), 756-766.
181. Lau, C.G.; Takeuchi, K.; Rodenas-Ruano, A.; Takayasu, Y.; Murphy, J.; Bennett, M.V.; Zukin, R.S. Regulation of NMDA receptor Ca2+ signalling and synaptic plasticity. Biochem. Soc. Trans., 2009, 37(pt. 6), 1369-1374.
182. Dwivedi, Y.; Rizavi, H.S.; Pandey, G.N. Differential effects of haloperidol and clozapine on [(3)H]cAMP binding, protein kinase A (PKA) activity, and mRNA and protein expression of selective regulatory and catalytic subunit isoforms of PKA in rat brain. J. Pharmacol. Exp. Ther., 2002, 301(1), 197-209.
183. Jardemark, K.E.; Ninan, I.; Liang, X.; Wang, R.Y. Protein kinase C is involved in clozapine's facilitation of N-methyl-D-aspartate- and electrically evoked responses in pyramidal cells of the medial prefrontal cortex. Neuroscience, 2003, 118(2), 501-512.
184. Rowe, B.A.; Schaffhauser, H.; Morales, S.; Lubbers, L.S.; Bonnefous, C.; Kamenecka, T.M.; McQuiston, J.; Daggett, L.P. Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site. J. Pharmacol. Exp. Ther., 2008, 326(1), 240-251.
185. Fraley, M.E. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin. Ther. Pat., 2009, 19(9), 1259-1275.